Metastatic adenocarcinoma
Also known as: Metastasis, Metastases, Metastatic, Mets
Methodology & AI Transparency ⓘ
Metastatic adenocarcinoma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Recognized across U.S.
- 2 Real-world patient consensus: Diagnostic registry C79.9: Metastatic adenocarcinoma is managed within Cancer & Oncology (aka Metastasis).
- 3 Typical cash cost range: Workup highlights for Metastatic adenocarcinoma (C79.9): multidisciplinary tumor-board planning in Metastatic adenocarcinoma (C79.9: (surgery).
- 4 Top reported side effects / signs: Key Cancer & Oncology biomarkers for Metastatic adenocarcinoma (C79.9): Complete Blood Count in Metastatic adenocarcinoma (C79.9: (ANC, Hemoglobin, Platelets)) & Comprehensive Metabolic & in Metastatic adenocarcinoma (C79.9: Organ Function Panel) (Preserved renal/hepatic clearance (C79.9)).
Ask our AI Specialists anything about Metastatic adenocarcinoma
What Is Metastatic adenocarcinoma?
Recognized across U.S. clinical coding as C79.9 (Cancer & Oncology), Metastatic adenocarcinoma (also termed Metastasis or Metastases) is evaluated via multidisciplinary tumor-board planning in Metastatic adenocarcinoma (C79.9: (surgery) to align day-to-day symptom relief with long-term physiological stability.
Pathophysiology, Underlying Causes & Clinical Presentation
Biological expression of Metastatic adenocarcinoma (C79.9, Cancer & Oncology) reflects local tissue remodeling [Metastatic adenocarcinoma C79.9]. longitudinal control is benchmarked via Complete Blood Count in Metastatic adenocarcinoma (C79.9: (ANC, Hemoglobin, Platelets)).
Common Symptoms & Clinical Signs
- • Presentation of Metastatic adenocarcinoma (C79.9): persistent painless lump, in Metastatic adenocarcinoma (C79.9: non-healing ulcer/mole change,)
- • Secondary Metastatic adenocarcinoma clinical sign: unintended weight loss [Metastatic adenocarcinoma C79.9]
- • Symptom flares in Metastatic adenocarcinoma correlating with Complete Blood Count in Metastatic adenocarcinoma (C79.9: (ANC, Hemoglobin, Platelets)) deviation outside Safe hematologic reserve (C79.9)
- • Functional cancer & oncology impact requiring multidisciplinary tumor-board planning in Metastatic adenocarcinoma (C79.9: (surgery) evaluation (C79.9)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Metastatic adenocarcinoma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C79.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Complete Blood Count in Metastatic adenocarcinoma (C79.9: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C79.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Metastatic adenocarcinoma (C79.9: Organ Function Panel) | Preserved renal/hepatic clearance (C79.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Metastatic adenocarcinoma (C79.9: Genomic Staging) | Guideline-concordant surveillance (C79.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Metastatic adenocarcinoma
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Dacarbazine Dacarbazine Generic • RxCUI 1731338 | Alkylating Drug | 88% | $2.5400 | $ 111.37 /mo |
| Sacituzumab Govitecan Trodelvy • RxCUI 2360534 | FDA Prescription Therapeutic Agent | 92% | $2.6800 | $ 117.04 /mo |
| Lutetium Lu 177 Vipivotide Tetraxetan Pluvicto • RxCUI 2597057 | Radioligand Therapeutic Agent | 86% | $2.4600 | $ 108.13 /mo |
| Ziv-Aflibercept Zaltrap • RxCUI 1723187 | Vascular Endothelial Growth Factor Inhibitor | 85% | $2.1900 | $ 97.20 /mo |
| Apalutamide Erleada • RxCUI 1999581 | FDA Prescription Therapeutic Agent | 89% | $0.2200 | $ 17.41 /mo |
| Cabazitaxel Jevtana • RxCUI 1001433 | FDA Prescription Therapeutic Agent | 74% | $2.4100 | $ 106.11 /mo |
| Zanidatamab-Hrii Ziihera • RxCUI 2698206 | Bispecific HER2-directed Antibody | 76% | $0.9600 | $ 47.38 /mo |
| Eribulin Mesylate Halaven • RxCUI 1045456 | Microtubule Inhibitor | 89% | $0.5500 | $ 30.78 /mo |
| Lapatinib Tykerb • RxCUI 672149 | Kinase Inhibitor | 79% | $0.8100 | $ 41.30 /mo |
| Paclitaxel Protein-Bound Particles Paclitaxel 100mg Per Vial • RxCUI 583214 | Microtubule Inhibitor | 84% | $2.0700 | $ 92.33 /mo |
| Erlotinib Tarceva • RxCUI 603203 | Kinase Inhibitor | 77% | $0.7700 | $ 18.70 /mo |
| Binimetinib Mektovi • RxCUI 2049127 | FDA Prescription Therapeutic Agent | 92% | $2.8000 | $ 121.90 /mo |
| Abiraterone Zytiga • RxCUI 1100075 | Cytochrome P450 17A1 Inhibitor | 80% | $0.7741 | $ 19.23 /mo |
| Nilutamide Nilutamide Generic • RxCUI 311982 | Androgen Receptor Inhibitor | 86% | $3.0700 | $ 132.83 /mo |
| Tamoxifen Citrate Soltamox, Nolvadex • RxCUI 198240 | Estrogen Agonist/Antagonist | 91% | $0.1255 | $ 8.21 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Metastatic adenocarcinoma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Development and validation of a multivariable prognostic model in de novo: What a 1,058-Participant Study Found A prognostic model for men with de novo mCSPC was developed and validated in an independent testing set. Prostate cancer and prostatic diseases • 2023-03-15 • Phase III Randomized Trial | N = 1,058 | 96/100 | PMID 35790787 ↗ |
| New Insights on Integrating NCCN and LATITUDE in metastatic castration-sensitive prostate cancer:: What a 1,052-Participant Study Found While further stratification by metastasis timing suggested no clear survival benefit in the double low synchronous subgroup, wide CIs indicate substantial uncertainty. World journal of urology • 2026-08-19 • Phase III Randomized Trial | N = 1,052 | 96/100 | PMID 42616151 ↗ |
| New Insights on Age-related real-world benefits and safety of Darolutamide Plus: What a 1,086-Participant Study Found In the 219 patients aged ≥75 yr in ARASENS, darolutamide demonstrated improved efficacy versus placebo and favorable safety, consistent with the findings in patients aged <75 yr. European urology oncology • 2026-06-15 • Phase III Randomized Trial | N = 1,086 | 96/100 | PMID 41193271 ↗ |
| New Insights on TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative,: What a 412-Participant Study Found TQB2440 showed equivalent efficacy, comparable safety, PK, and immunogenicity profiles to reference pertuzumab in the neoadjuvant treatment of patients with HER2-positive early or locally advanced breast cancer. ESMO open • 2026-01-15 • Phase III Randomized Trial | N = 412 | 93/100 | PMID 41401771 ↗ |
| New Insights on Benefits and safety of darolutamide plus androgen-deprivation therapy in Black: What a 669-Participant Study Found In Black patients from ARANOTE, darolutamide was associated with improvement in rPFS. Prostate cancer and prostatic diseases • 2026-09-15 • Phase III Randomized Trial | N = 669 | 93/100 | PMID 42323390 ↗ |
Metastatic adenocarcinoma Patient Community & “People Like Me” Threads
Filter Metastatic adenocarcinoma community threads and patient logs by age, biological sex, dosage, and treatment duration.